Direxion Daily S&P Biotech Bull 3X Shares LABU
223.75 USD +15.13 (+7.25%)
At closeNov 6, 2026, 7:48 PM EST
224.00 +0.25 +0.11%
After hours · Nov 6, 7:48 PM ET
204.54 Day range 226.50
117.62 52-week range 341.55
- YTD
- +40.38%
- 1 year
- +88.33%
- Market cap
- 1.11B
- YTD return
- +40.38%
- 1-year return
- +88.33%
- Volume
- 310.07K
- Avg volume
- 391.78K
- Open
- 209.90
- Previous close
- 208.62
- Day's range
- 204.54 – 226.50
- 52-week range
- 117.62 – 341.55
1Y +106.13 (+90.23%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 254.12
- 200-day average
- 217.80
Next earnings
Consensus EPS estimate 0.00.
About Direxion Daily S&P Biotech Bull 3X Shares
The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
News
EXCLUSIVE: Beyond The Magnificent Seven — Direxion's Egilinsky Reveals Top Sector Picks 
Pharma Catches Another Case Of M&A Fever 
As The Market Scrambles Over Tech And Trade Fears, ETF Fund Flow Signals Interesting Rotation 
CUREs For The Ordinary December Trade 
Heaps Of Healthy Health Care ETFs - A Conservative Way To Short The S&P 500
- Volatility Sparks Inflows To Inverse, Leveraged ETFs
- Leveraged ETF Rebalancing: It's Not As Bad As It Seems
Wild Ride For Leveraged Biotech ETFs Continues - ProShares Releases 2 New Leveraged Biotech ETFs
Your note
Sign in to keep a note on LABU — it syncs with the Stock Master app.